Suzhou, China | June 7, 2025 – The ISMIO 2025 Annual Conference of the International Society of Interventional and Multidisciplinary Oncology, featuring a dedicated symposium on tumor ablation and cryo-thermal techniques, successfully convened in Suzhou. Gathering leading oncology scholars from China, Russia, Turkey, Kazakhstan, Pakistan, and beyond, the conference launched in-depth discussions on minimally invasive techniques—including cryoablation and microwave ablation—for treating solid tumors.
In his opening address at ISMIO 2025, Academician Gao-Jun Teng of Zhongda Hospital, Southeast University heralded transformative advances in minimally invasive tumor therapies. "Ablation technologies – particularly cryoablation, radiofrequency ablation, microwave ablation, and emerging co-ablation systems – have achieved breakthrough progress," he stated. "These approaches significantly improve local tumor control while enabling precision, minimal invasiveness, and repeatability – paving new paradigms for multidisciplinary cancer care."
Highlighting China’s leadership in the field, Prof. Teng noted the nation’s evolution from early cryoablation to today’s advanced co-ablation systems: “Our rapid technological advancement stems from robust industry collaboration, with partners like Hygea Medical accelerating clinical translation and evidence generation.” Looking ahead, Academician Teng called for global synergy to optimize technical parameters, develop biomarker-guided personalized ablation protocols and launch multinational clinical trials.
Chaired by Prof. Fan Weijun (Sun Yat-sen University Cancer Center) and Prof. Niu Lizhi (Guangzhou Fuda Cancer Hospital), the session featured dynamic discussions on international best practices and technical implementation.
Pioneering Clinical Evidence
Russia: Prof. Alexey Zhao (P.A. Herzen Institute) demonstrated 14% 1-year survival in advanced cancers using cryoablation + chemotherapy (1% mortality). His open cryoablation technique enables precise ice-ball visualization for large tumors, with a showcased melanoma liver metastasis case achieving 60-month recurrence-free survival. "Cryoablation’s immunomodulatory effects transform multi-metastatic disease management," Prof. Zhao noted, highlighting China’s vascular safety protocols near critical arteries.
Turkey: Prof. Mehmet Mahir Atasoy reported 85% 5-year recurrence-free survival in early breast cancer using cryoablation + endocrine therapy, stating: *"PD-L1 inhibitors synergize with cryoablation’s immune activation in TMB-high/MSI-H patients."*
“For benign tumors, when lesions become symptomatic or continue to grow, minimally invasive approaches such as cryoablation, microwave ablation and RFA are ideal options.” Prof. Atasoy stated.
Turkey: Professor Saim Yilmaz from the Varlik Radiation Center in Turkey shared his team's five-year experience in the field of prostate cancer cryoablation. He noted that compared to traditional radical surgery, focused cryoablation targets only the tumor area, significantly reducing complications such as urinary incontinence and sexual dysfunction. "For prostate cancer recurring after radiotherapy, cryoablation is an ideal salvage treatment. Studies show its five-year overall survival rate can reach 74%-100%," he stated. He particularly emphasized the technique enables precise targeting without complex equipment and the procedure can be performed under local anesthesia, significantly reducing patient discomfort.
Kazakhstan: Professor Niyaz Malakayev introduced that Kazakhstan has progressively introduced radiofrequency and microwave ablation technologies since 2016. To date, his center has completed over 350 ablation treatments. "We introduced microwave ablation in 2023, and by 2024, 90% of early-stage liver cancer cases were treated with ablation. He revealed future plans to promote minimally invasive treatment technologies and specifically mentioned the desire to introduce cryoablation technology to enrich treatment options.
Pakistan: Professor Shahzad Bhatti from Mayo Hospital/ King Edward Medical University in Pakistan delivered a remote special report on tumor pain management, focusing on the application of interventional radiology techniques in relieving pain caused by abdominal malignancies. "For intractable pain caused by pancreatic cancer, liver cancer, etc., CT-guided celiac plexus block is an effective palliative treatment." "This technique provides significant pain relief in over 80% of patients, with a complication rate below 5%."
Prof. Niu Lizhi of Guangzhou Fuda Cancer Hospital presented landmark clinical advances in Hygea’s Co-ablation system. The technology uniquely integrates -196°C cryoablation with 85°C thermal therapy, generating a 5cm-diameter ice ball via single-probe deployment – surpassing conventional radiofrequency/microwave ablation in precision and safety.
"Our data in lung nodule treatment shows that for ground-glass opacities (GGOs) ≤2cm, the local control rate can reach 100%. These findings have been published in the Journal of Vascular and Interventional Radiology (JVIR)."
This international technical symposium serves not only as a platform for technological exchange but also as a starting point for global collaboration. Through multifaceted academic interactions, the conference comprehensively showcased cutting-edge international advancements in tumor ablation techniques, establishing a high-level communication bridge for the global oncology field, which will exert a significant impact on future clinical practices and research directions.
Hygea Medical Technology Co., Ltd.
Hygea Medical Technology Co., Ltd.
EN 
